Asitri Dashboard
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 23
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | ||
NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | ||
NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | ||
NCT03110822 | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | ||
NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | ||
NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone | ||
NCT00742404 | Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | ||
NCT03733691 | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | ||
NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | ||
NCT02188368 | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients | ||
NCT00316940 | Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | ||
NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | ||
NCT02294357 | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | ||
NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | ||
NCT06209606 | Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | ||
NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | ||
NCT01697839 | Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients | ||
NCT00743288 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | ||
NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | ||
NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | ||
NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | ||
NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | ||
NCT00317811 | Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma |